Andrea Fava, Jill Buyon, Laurence Magder, Jeff Hodgin, Avi Rosenberg, Dawit S Demeke, Deepak A Rao, Arnon Arazi, Alessandra Ida Celia, Chaim Putterman, Jennifer H Anolik, Jennifer Barnas, Maria Dall'Era, David Wofsy, Richard Furie, Diane Kamen, Kenneth Kalunian, Judith A James, Joel Guthridge, Mohamed G Atta, Jose Monroy Trujillo, Derek Fine, Robert Clancy, H Michael Belmont, Peter Izmirly, William Apruzzese, Daniel Goldman, Celine C Berthier, Paul Hoover, Nir Hacohen, Soumya Raychaudhuri, Anne Davidson, Betty Diamond, Michelle Petri
Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney disease and mortality. Better therapeutic strategies are needed as only 30%-40% of patients completely respond to treatment. Noninvasive biomarkers of intrarenal inflammation may guide more precise approaches. Because urine collects the byproducts of kidney inflammation, we studied the urine proteomic profiles of 225 patients with LN (573 samples) in the longitudinal Accelerating Medicines Partnership in RA/SLE cohort...
January 23, 2024: JCI Insight